MAIA Biotechnology Awarded $2.3 Million Grant by National
THIO-101 Phase 2 trial to enroll patients in the U.S. as part of the expansion of the study in third-line treatment for advanced non-small cell lung cancer (NSCLC) CHICAGO, Sept.…
Health Check: The latest ASX biotech IPO is out of the blocks
Nexsen is off and running on its great ASX marathon. Pic: Getty Images Diagnostic play Nexsen surges 47% on its ASX debut, after a well-supported raising Audeara has entered the…
Blending Ayurveda with Biotechnology: The Future of Wellness and health
The wellness industry is entering a new era. Modern medicine offers precision and speed, yet it struggles with lifestyle diseases and side effects. Ayurveda, India’s ancient system of healing, emphasizes…
Best Biotech ETFs to Watch Right Now
Want to invest in an exciting and fast-growing sector? Biotech offers an opportunity to do so. Hundreds of biotech companies are hard at work developing innovative therapies. Some could even…
Health Check: Biotech investors reckon Trump’s tariffs may not be such a bitter pill
A better day so far, but if pain persists, keep blaming Donald Trump. Pic: Getty Images CSL shares lead the local biotech sector’s recovery Nyrada and Chimeric report their trials…
Gene editing technologies leading to medical and biotech breakthroughs | Results Pack | CORDIS
DNA carries the genetic instructions that dictate how organisms develop and function – acting as a blueprint for life. By digging deeper into genetic differences and harnessing the power of…